Company intelligence / Profile preview
Vertanical
Gräfelfing, Bavaria, Germanyvertanical.com ↗
- Ownership
- Private
- Employees
- ~53
- Development stage
- Other
01
Overview
Vertanical has completed two large Phase 3 trials of its lead product, VER-01, a non-opioid, full-spectrum cannabis-based medicine for chronic low back pain. The trials demonstrated efficacy and safety compared to both placebo and opioids. Regulatory submissions are underway in Europe and the UK as of mid/late 2024, with US registration trials planned for 2025. The company positions VER-01 as a potential opioid alternative without dependency or abuse potential.[1][2][3][4][5]
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Full-spectrum cannabis extract (plant-derived cannabinoids)[5]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Vertanical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vertanical.